Anavex Life Sciences Corp (AVXL)

[12x]

The critical decision Anavex needs to make with its 140 million cash (1,000 patients in trials) is to whether commit the cash to a large Parkinson p3, split between AD and next AD p3, or do nothing till the either Rett or AD NDA can be submitted which would be end of 2023 the earliest.

It might be outdated but the average cost of doing AD trial is 130k per patient according to https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1002/alz.12450,